Stretta is by far the most widely studied and widely used of any minimally invasive treatment option for GERD, with studies showing a high rate of effectiveness and durability without the higher complication rates or costs of surgery. Stretta has been studied in academic institutions as well as in the community setting in sites around the world - showing an across the board consistency in rates of safety and effectiveness.

  • Lasting results from 4-10 years*
  • Up to 86% remain off daily PPIs at four years*
  • 64% of patients remain off daily PPIs at 10 years*
  • Up to 93% patient satisfaction*
  • More than 40 clinical studies
  • Four Randomized controlled trials
  • Multiple long-term studies
  • Has been proven effective in patients with already altered anatomy* 
    • GERD after bariatric procedures
    • GERD after anti-reflux surgery
  • Improvement in subjective and objective scores*
    • Improved GERD HRQL scores*
    • Reduction or elimination of medications*
    • Decreased acid exposure*
    • Regression of esophagitis observed*
  • Improvement in patients with LPR - Extraesophageal symptoms of GERD*
  • 25,000 procedures since inception
  • Lowest complication rate of any non-medical treatment for GERD*

Sages CSR Guideline Gives Stretta Strongest Grade Recommendation

Quality of Evidence: (+++)     
Grade Recommendation: Strong
The Society of American Gastrointestinal and Endoscopic Surgeons recently issued Clinical Guidelines that gave Stretta therapy for the treatment of GERD the highest GRADE recommendation. The SAGES Clinical Spotlight Review involved an in-depth analysis of available peer-reviewed clinical evidence, focusing on randomized, controlled studies, as well as long-term follow up showing durability of treatment effect.

Decreased Acid Exposure

“Analyses of symptom improvement vs. acid exposure suggested that symptom improvement was associated with decreased esophageal acid exposure. A comparison of patients before vs. after treatment indicated that acid exposure decreased significantly (median decrease, 2.4%; P=0.01) between baseline and 12 months for all treated patients (both initial active treatment and crossed-over patients).”
Corley et al. 2003 Gastroenterology (RCT)

“At 12 months, the mean HRQL scores of those off medications, the LES basal pressure, the 24-h pH scores, and the proton pump inhibitor (PPI) daily dose consumption were significantly improved from baseline...”
Aziz et al. 2009 Current Opinions Gastroenterology (RCT)

Increased Wall Thickness

“EUS demonstrates that LES muscle is significantly thickened after RF delivery...thickening may result in reduced compliance of the GE junction and contribute to its mechanism of action.”
Chang et al. 2001 Gastrointestinal Endoscopy

Increased Les Pressure - Decreased TLESRs

“RFe reduced the rate of postprandial transient LOS relaxations from 6.8 (5.7–8.1) (median (interquartile range) per hour to 5.2 (4.2–5.8) per hour (p<0.01), and increased mean basal LOS pressure from 5.2 (SEM 0.3) mm Hg to 8.0 (SEM 0.4) mm Hg (p<0.01).”
Tam et al. 2003 Gut

Decreased Tissue Compliance Without Fibrosis

“Stretta improved GERD symptoms and decreased GEJ compliance. Decreased GEJ compliance, which reflects altered LES neuromuscular function, may contribute to symptomatic benefit by decreasing refluxate volume.”
Arts et al. 2011 American Journal of Gastroenterology (RCT)

*While clinical studies support the safety and effectiveness of Stretta for patients with chronic GERD (gastroesophageal reflux disease), individual results will vary from case to case and there are no guarantees of successful outcome.

Healthcare Professionals » How Does Stretta Treat GERD? » Clinical Highlights